AU2001262943A1 - Methods for drug discovery, disease treatment, and diagnosis using metabolomics - Google Patents

Methods for drug discovery, disease treatment, and diagnosis using metabolomics

Info

Publication number
AU2001262943A1
AU2001262943A1 AU2001262943A AU6294301A AU2001262943A1 AU 2001262943 A1 AU2001262943 A1 AU 2001262943A1 AU 2001262943 A AU2001262943 A AU 2001262943A AU 6294301 A AU6294301 A AU 6294301A AU 2001262943 A1 AU2001262943 A1 AU 2001262943A1
Authority
AU
Australia
Prior art keywords
metabolomics
diagnosis
methods
drug discovery
disease treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001262943A
Inventor
Rima Kaddurah-Daouk
Bruce S. Kristal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolon Inc
Original Assignee
Metabolon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27498145&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001262943(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Metabolon Inc filed Critical Metabolon Inc
Publication of AU2001262943A1 publication Critical patent/AU2001262943A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Virology (AREA)
AU2001262943A 2000-04-14 2001-04-13 Methods for drug discovery, disease treatment, and diagnosis using metabolomics Abandoned AU2001262943A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US19708500P 2000-04-14 2000-04-14
US19711700P 2000-04-14 2000-04-14
US60197117 2000-04-14
US60197085 2000-04-14
US23954100P 2000-10-10 2000-10-10
US60239541 2000-10-10
US23934000P 2000-10-11 2000-10-11
US60239340 2000-10-11
PCT/US2001/012097 WO2001078652A2 (en) 2000-04-14 2001-04-13 Methods for drug discovery, disease treatment, and diagnosis using metabolomics

Publications (1)

Publication Number Publication Date
AU2001262943A1 true AU2001262943A1 (en) 2001-10-30

Family

ID=27498145

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001262943A Abandoned AU2001262943A1 (en) 2000-04-14 2001-04-13 Methods for drug discovery, disease treatment, and diagnosis using metabolomics

Country Status (6)

Country Link
US (3) US20020009740A1 (en)
EP (2) EP1285092A4 (en)
JP (2) JP2003530130A (en)
AU (1) AU2001262943A1 (en)
CA (1) CA2443806A1 (en)
WO (1) WO2001078652A2 (en)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2298181C (en) 2000-02-02 2006-09-19 Dayan Burke Goodnough Non-targeted complex sample analysis
AU2001262943A1 (en) 2000-04-14 2001-10-30 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US7329489B2 (en) * 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
DE10054055A1 (en) 2000-10-31 2002-05-23 Nmi Univ Tuebingen Methods for analyzing proteins
WO2003046798A1 (en) * 2001-11-21 2003-06-05 Paradigm Genetics, Inc. Methods and systems for analyzing complex biological systems
WO2003078574A2 (en) * 2002-03-11 2003-09-25 Lipomics Technologies, Inc. Novel metabolic targets and markers
US7618788B2 (en) 2002-05-10 2009-11-17 Millipore Corporation Proteome epitope tags and methods of use thereof in protein modification analysis
US7460960B2 (en) 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
US9740817B1 (en) 2002-10-18 2017-08-22 Dennis Sunga Fernandez Apparatus for biological sensing and alerting of pharmaco-genomic mutation
WO2004038381A2 (en) * 2002-10-25 2004-05-06 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
KR100686910B1 (en) 2002-12-09 2007-02-26 아지노모토 가부시키가이샤 Organism condition information processor, organism condition information processing method, organism condition information managing system and recording medium
US20050143628A1 (en) * 2003-06-18 2005-06-30 Xudong Dai Methods for characterizing tissue or organ condition or status
US8346482B2 (en) 2003-08-22 2013-01-01 Fernandez Dennis S Integrated biosensor and simulation system for diagnosis and therapy
US20050059023A1 (en) * 2003-09-16 2005-03-17 Cantor Thomas L. Methods and kits for monitoring resistance to therapeutic agents
WO2005042761A2 (en) * 2003-10-23 2005-05-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Biomarkers for amyotrophic lateral sclerosis
WO2005050224A2 (en) * 2003-11-13 2005-06-02 Epitome Biosystems Inc. Small molecule and peptide arrays and uses thereof
CA2598529A1 (en) * 2005-02-22 2006-08-31 Mcgill University Oxidative stress measurement device and related methods
WO2006112841A1 (en) * 2005-04-19 2006-10-26 The Scripps Research Institute Methods for metabolite profiling
JP5020491B2 (en) * 2005-05-02 2012-09-05 株式会社 Ｊｅｏｌ Ｒｅｓｏｎａｎｃｅ NMR data processing apparatus and method
CA2608963C (en) * 2005-06-30 2014-08-26 Biocrates Life Sciences Ag Apparatus and method for analyzing a metabolite profile
US7949475B2 (en) * 2005-08-08 2011-05-24 Metabolon Inc. System and method for analyzing metabolomic data
JP4950993B2 (en) 2005-08-08 2012-06-13 メタボロン インコーポレイテッド System and method for comparing and editing metabolite data from multiple samples using a computer system database
EP1931995A4 (en) 2005-09-12 2010-08-04 Phenomenome Discoveries Inc Methods for the diagnosis of colorectal cancer and ovarian cancer health states
WO2007050318A2 (en) * 2005-10-24 2007-05-03 Duke University Lipidomics approaches for central nervous system disorders
US20070162992A1 (en) * 2006-01-09 2007-07-12 Mcgill University Metabolomic determination in assisted reproductive technology
US9157914B2 (en) * 2006-01-10 2015-10-13 Colgate-Palmolive Company Methods of modulating cell surface receptors to prevent or reduce inflammation
EP1998789A4 (en) 2006-02-28 2009-04-22 Metabolon Inc Biomarkers for amyotrophic lateral sclerosis and methods using the same
ATE535535T1 (en) 2006-02-28 2011-12-15 Phenomenome Discoveries Inc METHODS FOR DIAGNOSING DEMENTIA AND OTHER NEUROLOGICAL DISEASES
AU2013273746A1 (en) * 2006-02-28 2014-02-20 Phenomenome Discoveries Inc. Methods for the diagnosis of dementia and other neurological disorders
US7561975B2 (en) * 2006-03-21 2009-07-14 Metabolon, Inc. System, method, and computer program product for analyzing spectrometry data to identify and quantify individual components in a sample
US7855057B2 (en) 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
KR20090006837A (en) * 2006-03-24 2009-01-15 페노미넘 디스커버리스 인코포레이티드 Blomarkers useful for diagnosing prostate cancer, and methods thereof
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US8137977B2 (en) * 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
WO2007127192A2 (en) * 2006-04-24 2007-11-08 Duke University Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
US8394354B2 (en) * 2006-05-09 2013-03-12 Metabolon, Inc. Biomarkers for depression and methods using the same
AU2007253899A1 (en) 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of R(+) and S(-) pramipexole and methods of using the same
WO2007137410A1 (en) * 2006-05-26 2007-12-06 Phenomenome Discoveries Inc. Biomarkers for diagnosing multiple sclerosis, and methods thereof
WO2008016101A1 (en) 2006-08-04 2008-02-07 Ajinomoto Co., Inc. Method for evaluation of stress, stress evaluation apparatus, stress evaluation method, stress evaluation system, stress evaluation program, and recording medium
WO2008015929A1 (en) * 2006-08-04 2008-02-07 Ajinomoto Co., Inc. Metabolic syndrome evaluation method, metabolic syndrome evaluation apparatus, metabolic syndrome evaluation method, metabolic syndrome evaluation system, metabolic syndrome evaluation program and recording medium, and method for search for prophylactic/ameliorating substance for metabolic syndrome
US20080183101A1 (en) * 2006-08-17 2008-07-31 Jonathan Richard Stonehouse Salivary analysis
WO2008033575A2 (en) * 2006-09-15 2008-03-20 Metabolon, Inc. Methods of identifying biochemical pathways
US20090075284A1 (en) * 2006-09-19 2009-03-19 The Regents Of The University Of Michigan Metabolomic profiling of prostate cancer
AU2007299846B2 (en) * 2006-09-19 2014-11-20 Metabolon, Inc. Biomarkers for prostate cancer and methods using the same
EP2813580A1 (en) 2006-10-13 2014-12-17 Metabolon, Inc. Biomarkers related to metabolic age and methods using the same
EP1923806A1 (en) * 2006-11-14 2008-05-21 Metanomics GmbH Fast metabolomic analysis and system therefor
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
SG173418A1 (en) 2007-02-08 2011-08-29 Phenomenome Discoveries Inc Methods for the treatment of senile dementia of the alzheimer's type
PT2129396E (en) 2007-02-16 2013-11-18 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
CN101715443A (en) 2007-03-14 2010-05-26 诺普神经科学股份有限公司 synthesis of chirally purified substituted benzothiazole diamines
JP5116348B2 (en) * 2007-04-12 2013-01-09 花王株式会社 Test substance evaluation or screening method
JP2010527449A (en) * 2007-05-15 2010-08-12 ブライハム アンド ウィミンズ ホスピタル，インコーポレーテッド Identification of oxidatively modified peptide sequences in the proteome
EP2153232A1 (en) * 2007-05-18 2010-02-17 Duke University Serum biomarkers for the early detection of lung cancer
JPWO2009001862A1 (en) 2007-06-25 2010-08-26 味の素株式会社 Evaluation method of visceral fat accumulation
JP5701601B2 (en) 2007-07-17 2015-04-15 メタボロン インコーポレイテッド Biomarkers for pre-diabetes, cardiovascular disease and other metabolic syndrome related disorders and methods of use thereof
AU2008289172B2 (en) * 2007-08-16 2013-01-17 Metabolon, Inc. Metabolomic profiling of prostate cancer
JPWO2009054350A1 (en) * 2007-10-25 2011-03-03 味の素株式会社 Glucose tolerance abnormality evaluation method, glucose tolerance abnormality evaluation device, glucose tolerance abnormality evaluation method, glucose tolerance abnormality evaluation system, glucose tolerance abnormality evaluation program and recording medium, and glucose tolerance abnormality prevention / improvement method
WO2009059150A2 (en) 2007-11-02 2009-05-07 Metabolon, Inc. Biomarkers for fatty liver disease and methods using the same
EP2279417B1 (en) * 2008-05-28 2016-07-20 Georgia Tech Research Corporation Metabolic biomarkers for ovarian cancer and methods of use thereof
WO2010022140A1 (en) 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
US8440459B2 (en) * 2008-10-09 2013-05-14 Allan Kumar Mishra Platelet rich plasma formulations for cardiac treatments
AR076041A1 (en) 2009-04-01 2011-05-11 Colgate Palmolive Co PROTEIN BIOMARKERS FOR THE DIAGNOSIS OF SOFT TISSUE DISEASES AND AS THERAPEUTIC OBJECTIVES FOR ORAL CARE INTERVENTIONS
MX2011008959A (en) 2009-04-01 2011-09-27 Colgate Palmolive Co Anti-biofilm carbonate compounds for use in oral care compositions.
TWI405565B (en) 2009-04-01 2013-08-21 Colgate Palmolive Co Anti bone-loss and anti attachment-loss effects of an oral composition
BRPI0924915A2 (en) 2009-04-01 2015-07-07 Colgate Palmolive Co Method and composition for providing enhanced oral and systemic health care benefits and method and composition for regulating up or down regulating the metabolic of periodontal disease.
CN102667789A (en) 2009-10-02 2012-09-12 梅塔博隆有限公司 Apparatus and associated method for analyzing small molecule components in a complex mixture
US20110151497A1 (en) * 2009-12-22 2011-06-23 The Regents Of The University Of Michigan Metabolomic profiling of prostate cancer
EP2544680B1 (en) 2010-03-11 2015-01-14 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative breast cancer
WO2011130385A1 (en) 2010-04-13 2011-10-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Biomarkers for hepatocellular cancer
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
JP5920827B2 (en) * 2012-06-21 2016-05-18 国立研究開発法人農業・食品産業技術総合研究機構 Identification method of disease resistant variety line
EP2901392B1 (en) * 2012-09-25 2018-11-07 Google LLC Securing personal identification numbers for mobile payment applications by combining with random components
EP2951313B1 (en) 2013-01-31 2018-03-07 Metabolon, Inc. Biomarkers related to insulin resistance progression and methods using the same
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
JP6763770B2 (en) 2013-07-09 2020-09-30 ステミナ バイオマーカー ディスカバリー， インコーポレイテッド Biomarker for autism spectrum disorders
JP6329717B2 (en) 2013-07-12 2018-05-23 ノップ バイオサイエンシーズ エルエルシー Treatment of high eosinophil levels and / or high basophil levels
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
HUE055850T2 (en) 2013-08-13 2022-01-28 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
AU2014306683B2 (en) 2013-08-13 2017-10-12 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
CN106537145B (en) 2014-04-08 2020-08-25 麦特博隆股份有限公司 Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
EP3149762A1 (en) 2014-05-30 2017-04-05 Metabolon, Inc. Method for analyzing small molecule components of a complex mixture in a multi-sample process, and associated apparatus and computer program product
CA2965874A1 (en) * 2014-11-05 2016-05-12 Metabolon, Inc. System, method and apparatus for determining the effect of genetic variants
JP2018502286A (en) 2014-11-19 2018-01-25 メタボロン，インコーポレイテッド Biomarker for fatty liver disease and method of use thereof
EP3254105B1 (en) * 2015-02-06 2019-08-07 Metabolon, Inc. Diagnostic methods, therapeutic agents and uses thereof
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
JP6747095B2 (en) * 2016-06-24 2020-08-26 ブラザー工業株式会社 Information processing program and information processing apparatus
US11154619B2 (en) 2017-02-17 2021-10-26 Creighton University Liposomal compositions with light illumination-induced drug release
EP3713478A4 (en) 2017-11-22 2021-11-03 Mayo Foundation for Medical Education and Research Methods and materials for assessing and treating obesity
PT3724654T (en) 2017-12-15 2024-06-20 Metabolon Inc Method for analyzing small molecule components of a complex mixture, and associated apparatus and computer program product
WO2019195638A1 (en) 2018-04-04 2019-10-10 Human Longevity, Inc. Systems and methods for measuring obesity using metabolome analysis
US11693005B2 (en) 2018-08-07 2023-07-04 Florida Atlantic University Board Of Trustees Methods for identifying treatments that reduce the actions of substances of abuse and addiction
US20200116657A1 (en) * 2018-10-15 2020-04-16 Olaris, Inc. Nmr-metabolite-signature for identifying cancer patients resistant to cdk4/6 inhibitors, endocrine therapy and anti-her2 therapy
US12100484B2 (en) 2021-11-01 2024-09-24 Matterworks Inc Methods and compositions for analyte quantification
US20230137741A1 (en) 2021-11-01 2023-05-04 Matterworks Inc Methods and compositions for analyte quantification

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32920E (en) 1978-01-11 1989-05-09 Esa, Inc. Electrochemical testing system and method
US4511659A (en) 1983-03-04 1985-04-16 Esa, Inc. Liquid chromatograph with electrochemical detector and method
US6210970B1 (en) * 1980-01-14 2001-04-03 Esa, Inc. Method of diagnosing or categorizing disorders from biochemical profiles
US6194217B1 (en) * 1980-01-14 2001-02-27 Esa, Inc. Method of diagnosing or categorizing disorders from biochemical profiles
US5104639A (en) 1980-01-14 1992-04-14 Esa, Inc. Method for biological testing and/or developing pharmaceuticals for treatment of disorders using electrochromatography
US4863873A (en) * 1980-01-14 1989-09-05 Esa, Inc. Method for biological testing and/or developing pharmaceuticals for treatment of disorders
DE3587091T2 (en) 1984-11-13 1993-06-03 Esa Inc DEVELOPMENT METHOD FOR DRUG TREATMENT MEDICINES.
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
EP0562025B1 (en) 1990-12-06 2001-02-07 Affymetrix, Inc. (a Delaware Corporation) Compounds and their use in a binary synthesis strategy
DE69214628T2 (en) * 1991-01-18 1997-05-22 Esa Inc Method of diagnosing disorders of body functions using biochemical profiles
US5977083A (en) * 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
JPH06506000A (en) 1991-12-02 1994-07-07 山川貿易株式会社 Aqueous synthetic biological extract
US5290420A (en) 1992-08-12 1994-03-01 Esa, Inc. Sampling system and analysis cell for stripping voltammetry
US5541310A (en) 1993-05-13 1996-07-30 Ciba-Geigy Corporation Herbicide resistant plants
US5861242A (en) 1993-06-25 1999-01-19 Affymetrix, Inc. Array of nucleic acid probes on biological chips for diagnosis of HIV and methods of using the same
US6027880A (en) 1995-08-02 2000-02-22 Affymetrix, Inc. Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
US5536639A (en) * 1994-03-25 1996-07-16 Cephalon, Inc. Methods for detecting calpain activation by detection of calpain activated spectrin breakdown products
US5565323A (en) * 1994-03-30 1996-10-15 Mitokor Cytochrome oxidase mutations aiding diagnosis of sporadic alzheimer's disease
CA2211131A1 (en) 1995-01-23 1996-08-01 Microcide Pharmaceuticals, Inc. Screening for modulators of biomolecules
US6319668B1 (en) 1995-04-25 2001-11-20 Discovery Partners International Method for tagging and screening molecules
US5908609A (en) 1996-06-10 1999-06-01 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
DE19624802A1 (en) 1996-06-21 1998-01-02 Forssmann Wolf Georg Method for the direct diagnostic detection of pathogenic, genetically determined point mutations in proteins in heart diseases by chemical and physical methods, especially the direct and indirect coupling of high pressure liquid chromatography and mass spectrometry
GB9700012D0 (en) 1997-01-02 1997-02-19 Aromascan Plc Improvements in the detection of bacteria
US6087090A (en) 1997-02-25 2000-07-11 Celtrix Pharmaceuticals, Inc. Methods for predicting drug response
US5824467A (en) 1997-02-25 1998-10-20 Celtrix Pharmaceuticals Methods for predicting drug response
EP1032830A1 (en) 1997-11-20 2000-09-06 ESA, Inc. Electrochemical analysis system
EP1049796A1 (en) 1997-12-18 2000-11-08 Sepracor, Inc. Methods for the simultaneous identification of novel biological targets and lead structures for drug development
HUP0100315A3 (en) 1998-01-22 2003-04-28 Nat Res Council Canada Ottawa Methods and compositions for modifying levels of secondary metabolic compounds in plants
DE19802576B4 (en) * 1998-01-23 2004-10-28 Xerion Pharmaceuticals Ag Methods for the simultaneous identification of proteins and their binding partners
EP1051624A4 (en) 1998-01-29 2002-05-02 Glaucus Proteomics B V High density arrays for proteome analysis and methods and compositions therefor
DE69934222T2 (en) * 1998-02-25 2007-10-25 The United States Government As Represented By The Department Human Services CELLULAR ARRANGEMENTS FOR FAST MOLECULAR PROFILE IDENTIFICATION
CA2291889A1 (en) * 1998-03-30 1999-10-07 Esa, Inc. Methodology for predicting and/or diagnosing disease
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6218117B1 (en) * 1998-06-15 2001-04-17 Mitokor Compositions and methods for identifying agents that quantitatively alter detectable extramitochondrial DNA:mitochondrial DNA ratios
DE69933679T2 (en) * 1998-08-12 2007-08-23 Zycos Inc., Cambridge PRESENTATION OF THE PROFILE AND CATALOGIZATION OF EXPRESSED PROTEIN MARKERS
US20030049613A1 (en) * 1998-08-17 2003-03-13 Manuel Perucho Methods for identifying somatic changes in genomic sequences useful for cancer diagnosis and prognosis
DE69914770T2 (en) 1998-08-20 2005-05-12 The Johns Hopkins University School Of Medicine MITOCHONDRIALE, TUMORMARKER SUITABLE MUTATIONS ONLY BASED ON A BASE PAIR
US6053866A (en) * 1998-10-29 2000-04-25 Mcleod; Malcolm N. Method for facilitating diagnosis of a psychiatric disorder
US6258605B1 (en) 1999-03-26 2001-07-10 Neo Gen Screening, Inc. Clinical method for the genetic screening of newborns using tandem mass spectrometry
AU2054000A (en) 1999-02-26 2000-09-14 Lipomed, Inc. Methods, systems, and computer program products for analyzing and presenting risk assessment results based on nmr lipoprotein analysis of blood
EP1161551A2 (en) 1999-03-17 2001-12-12 Paradigm Genetics Inc. Methods and materials for the rapid and high volume production of a gene knock-out library in an organism
WO2000065472A1 (en) 1999-04-26 2000-11-02 Surromed, Inc. Phenotype and biological marker identification system
WO2000065039A2 (en) 1999-04-28 2000-11-02 Syngenta Participations Ag Identification of dna control elements responsive to specific stimuli
US6168933B1 (en) 1999-06-08 2001-01-02 Incyte Pharmaceuticals, Inc. Phospholipid transfer protein
WO2001000819A1 (en) 1999-06-25 2001-01-04 Chauhan, Sarita Targeted gene replacements in enteric bacteria using linear dna
US6376210B1 (en) 1999-07-06 2002-04-23 General Atomics Methods and compositions for assaying analytes
US6350588B1 (en) 1999-07-20 2002-02-26 Micrology Laboratories, Llc Test media and quantitative or qualitative method for identification and differentiation of biological materials in a test sample
DE19935967A1 (en) 1999-07-30 2001-02-01 Bayer Ag New DNA encoding Arabidopsis thaliana 1-deoxy-D-xylulose-5-phosphate reductoisomerase for identifying modulators of the enzyme that can be used as herbicides, antibiotic or anti-malarial agents
AU6826900A (en) 1999-07-30 2001-02-19 Bayer Aktiengesellschaft Method of determining the activity of 1-deoxy-d-xylulose-5-phosphate reductoisomerase and 1-deoxy-d-xylulose-5-phosphate synthase
AU6505600A (en) 1999-08-03 2001-02-19 Paradigm Genetics, Inc. Methodology for identifying plants and other organisms having traits differing from a normal population
WO2001018627A2 (en) 1999-09-06 2001-03-15 National University Of Singapore Method and apparatus for computer automated detection of protein and nucleic acid targets of a chemical compound
US6677160B1 (en) 1999-09-29 2004-01-13 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
EP1242339B1 (en) 1999-09-29 2009-07-29 Nerviano Medical Sciences S.r.l. Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
ATE366322T1 (en) 1999-09-30 2007-07-15 Univ Guelph NEW ENZYMES AND METABOLITES IN SKATOL METABOLISM
US7225082B1 (en) 1999-10-01 2007-05-29 Oxonica, Inc. Colloidal rod particles as nanobar codes
AU2064001A (en) 1999-12-06 2001-06-12 National Center For Genome Resources System and method for metabolic profiling
US6566086B1 (en) 2000-01-28 2003-05-20 Fal Diagnostics Diagnostic kit for detecting creatine levels
US6713298B2 (en) 2000-01-31 2004-03-30 Board Of Regents, The University Of Texas System Method and apparatus for the delivery of samples to a chemical sensor array
CA2298181C (en) 2000-02-02 2006-09-19 Dayan Burke Goodnough Non-targeted complex sample analysis
GB2360282A (en) 2000-03-17 2001-09-19 Bioinvent Int Ab Making and using micro-arrays of biological materials
CA2376140A1 (en) 2000-03-28 2001-10-04 Thomas H. Barrett, Jr. Methods, systems and computer program products for dynamic scheduling and matrix collecting of data about samples
US6617494B2 (en) 2000-04-12 2003-09-09 Paradigm Genetics, Inc. Methods for identifying transgenic plants using morphological markers
US7329489B2 (en) * 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
AU2001262943A1 (en) 2000-04-14 2001-10-30 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
SE0001670D0 (en) 2000-05-04 2000-05-04 Forskarpatent I Syd Ab Mass spectrometry-based biosensor
AU2001275870A1 (en) 2000-07-06 2002-01-21 Fal Diagnostics Methods and kits for the detection of arginine compounds
US6680203B2 (en) 2000-07-10 2004-01-20 Esperion Therapeutics, Inc. Fourier transform mass spectrometry of complex biological samples
US6326164B1 (en) 2000-07-27 2001-12-04 Paradigm Genetics, Inc. Methods for determining deoxyxylulose 5-phosphate synthase activity
WO2002009836A2 (en) 2000-08-01 2002-02-07 Surromed, Inc. Methods for solid phase nanoextraction and desorption
US6753135B2 (en) 2000-09-20 2004-06-22 Surromed, Inc. Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders
GB0031566D0 (en) 2000-12-22 2001-02-07 Mets Ometrix Methods for spectral analysis and their applications
AU2002306862A1 (en) 2001-03-23 2002-11-05 Children's Medical Center Corporation Selective deposition of materials on contoured surfaces
CA2445106A1 (en) 2001-04-23 2002-10-31 Metabometrix Limited Methods for analysis of spectral data and their applications: osteoporosis
EP1444524A2 (en) 2001-09-14 2004-08-11 Paradigm Genetics Inc. Methods for the identification of modulators of magnesium chelatase expression or activity in plants
WO2004038381A2 (en) 2002-10-25 2004-05-06 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
WO2006086731A2 (en) 2005-02-09 2006-08-17 The Gov't.T Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services Method for identifying the risk of preterm delivery

Also Published As

Publication number Publication date
EP1285092A4 (en) 2003-07-16
EP2330219A3 (en) 2011-11-23
WO2001078652A2 (en) 2001-10-25
US20070026389A1 (en) 2007-02-01
US20020009740A1 (en) 2002-01-24
JP2012185166A (en) 2012-09-27
CA2443806A1 (en) 2002-10-25
EP1285092A2 (en) 2003-02-26
US20040146853A1 (en) 2004-07-29
WO2001078652A3 (en) 2002-02-07
US7005255B2 (en) 2006-02-28
EP2330219A2 (en) 2011-06-08
JP2003530130A (en) 2003-10-14
US7635556B2 (en) 2009-12-22

Similar Documents

Publication Publication Date Title
AU2001262943A1 (en) Methods for drug discovery, disease treatment, and diagnosis using metabolomics
AU2001275177A1 (en) Cardiac disease treatment and device
AU2001253565A1 (en) Cardiac disease treatment and device
AU2001275176A1 (en) Cardiac disease treatment and device
AU2001281369A1 (en) Cardiac disease treatment and device
AU2001240753A1 (en) Lipid nanocapsules, preparation method and use as medicine
HK1061679A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-ibe derivatives, their preparation and their therapeutic use.
AU2002340999A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
AU2002338265A1 (en) Molecules for disease detection and treatment
AU2003286726A1 (en) Methods for drug discovery, disease treatment, and diagnosis using metabolomics
AU2001264042A1 (en) 1,4-diazabicyclo(3.2.2)nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof
AU2001264044A1 (en) 1,4-diazabicyclo(3.2.2)nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
AU2001235595A1 (en) 4-heteroaryl-1,4-diazabicyclo(3.2.2)nonane, preparation and therapeutic use thereof
AU2000265525A1 (en) Medicament for treating intestinal diseases
AU2002239664A1 (en) Method for drug development using individual patient response
AU2003210266A1 (en) Treatment, diagnosis and imaging of disease
MXPA03006249A (en) 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof.
AU2002233407A1 (en) 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof
AU2002329784A1 (en) Molecules for disease detection and treatment
AU4654500A (en) Prevention, diagnosis and treatment of lyme disease
AU4418400A (en) Treatment, imaging and diagnosis of disease using an agent which binds alfa5-integrin
AU2002364890A1 (en) Molecules for disease detection and treatment
AU2001277737A1 (en) Novel substance having physiological activity, process for producing the same, and use
AU2001241709A1 (en) Molecules for disease detection and treatment
AU2001284084A1 (en) Polyfluoroalkyltriazole derivatives, preparation and therapeutic use thereof